Autoimmune Hepatitis Stem Cell Treatment India

EDITORIAL GOVERNANCE & MEDICAL REVIEW

Clinical E-E-A-T Verified

✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
✓
Clinical Governance Protocol: SOP-AIH-06 (Investigational Cellular Protocol)

• Last Clinical Review: September 2026 | Next Scheduled Re-Audit: March 2027

View Editorial Standards →

Condition Overview & Research Scope

Clinical Overview & Biological Mechanism

Pathology, cellular action of Mesenchymal Stem Cells (MSCs), and investigational intent

The Pathology:

Autoimmune Hepatitis (AIH) is a progressive, immune-mediated necroinflammatory liver disease characterized by circulating autoantibodies (ANA, SMA, anti-LKM-1, or SLA), hypergammaglobulinemia (elevated serum IgG), histological interface hepatitis, and progressive hepatic fibrosis or cirrhosis.

The Cellular Mechanism:

Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act primarily via paracrine immunomodulation and secretome-mediated hepatoprotection:

Suppress hyperactive cytotoxic CD4+ and CD8+ T-lymphocyte proliferation while promoting regulatory T-cell (Treg) expansion.
Inhibit transforming growth factor-beta (TGF-$\beta$) signaling and deactivate hepatic stellate cells (HSCs), helping to attenuate excess extracellular collagen deposition.
Release cytoprotective trophic factors (HGF, VEGF, IL-10, PGE2) that promote microvascular endothelial recovery and hepatocyte survival.

Investigational Intent:

This is an adjunctive, non-curative cellular intervention. It does not rewrite autoimmune genetic susceptibility or replace standard immunosuppressive maintenance, but seeks to calm hepatic necroinflammation, assist biochemical remission, and support parenchymal stabilization in refractory or steroid-dependent cases.

Clinical Eligibility & Selection Criteria

Candidate Screening & Safety Triage

Inclusion criteria, absolute safety exclusions, and pre-arrival diagnostic clearance

Eligible Profiles for Evaluation:

Clinically, serologically, and histologically confirmed Autoimmune Hepatitis (Type 1 or Type 2) diagnosed via revised International Autoimmune Hepatitis Group (IAIHG) criteria.
Incomplete biochemical response, frequent inflammatory relapses, or severe steroid intolerance/dependence despite maintenance therapy (Azathioprine, Budesonide/Prednisolone, or Mycophenolate Mofetil).

Compensated hepatic function: Child-Pugh Class A, baseline MELD score $< 12$, platelets $\ge 70,000/\mu\text{L}$, and INR $\le 1.5$; clinically cleared for commercial flights.

Absolute Exclusion Criteria (Non-Candidates):

Decompensated cirrhosis (Child-Pugh Class B/C, refractory ascites, active variceal bleeding, or recurrent hepatic encephalopathy; requires specialized liver transplant evaluation, not elective outpatient cell therapy).
Acute fulminant liver failure, spontaneous bacterial peritonitis (SBP), or active systemic sepsis.
Undiagnosed hepatic mass lesions, confirmed hepatocellular carcinoma (HCC), or concurrent active viral hepatitis (HBV/HCV/HDV).

Pre-Arrival Medical Clearance:

International candidates must submit liver biopsy histopathology reports, recent abdominal Doppler ultrasound/FibroScan records, comprehensive liver chemistry (ALT, AST, Total Bilirubin, Albumin, INR), quantitative serum IgG levels, and endoscopy reports ruling out high-risk gastroesophageal varices for hepatology board review before travel booking.

Targeted Clinical Objectives

Potential Improvements & Realistic Clinical Boundaries

Reported functional goals alongside documented non-responder rates and realistic limits

Biological responses depend on the degree of baseline architectural distortion and histological fibrosis. Stem cell therapy is adjunctive; results are never guaranteed.

Transaminase Stabilization: Trend toward biochemical normalization of serum ALT, AST, and total bilirubin levels.

Immunoglobulin Modulation: Potential reduction or stabilization of elevated serum IgG levels alongside maintenance immunosuppression.

Fatigue Alleviation: Noticeable decrease in chronic autoimmune hepatic fatigue and systemic malaise.

Inflammatory Mitigation: Reduction in ongoing interface necroinflammation, helping protect surviving functional liver parenchyma.

Fibrogenesis Attenuation: Downregulation of hepatic fibrogenic cascades, supporting stable liver stiffness scores over time.

Documented Clinical Realities:

No Permanent Cure: MSCs do not rewrite immune memory permanently; therapy aims for biochemical and symptomatic stabilization.

Non-Responder Rate: An estimated 25–35% of patients experience minimal functional or biochemical response, and autoimmune activity may persist.

Biological Response Lag: Immunomodulatory and tissue signaling effects require 8 to 12 weeks to manifest; immediate biochemical clearance should not be expected.

Safety Profile & Governance

Clinical Safety Profile & Anticipated Adverse Reactions

Anticipated transient reactions, procedural safeguards, and long-term surveillance

Clinical-grade, unmanipulated allogeneic UC-MSCs possess an established safety record, but patients and families must understand potential transient reactions:

Common & Transient (Days 1–3):

Low-grade post-infusion fever ($< 38^\circ\text{C}$ / $100.4^\circ\text{F}$), temporary fatigue, mild nausea, or cannula site soreness.

Rare Risks:

Allergic hypersensitivity reactions or blood pressure fluctuations (managed under continuous bedside vital monitoring).

Hepatic Safety Precautions: Patients undergo baseline coagulation and liver enzyme monitoring prior to each infusion, with continuous access to tertiary intensive care backup.

Treatment Schedule & Roadmap

Step-by-Step Treatment Schedule & In-Hospital Workflow

Structured clinical itinerary during your stay in India (4 to 6 Days)

Total Program Length: 4 to 6 days on an outpatient hospital daycare and monitored recovery basis.

Day 1 (Comprehensive Hepatology Workup):

In-person evaluation by a board-certified hepatologist; Child-Pugh and MELD score baseline assessment.

Confirmatory safety checks: CBC, complete liver panel, coagulation profile (PT/INR), renal panel, and bedside abdominal ultrasound.

Days 2–3 (Cell Delivery & Supportive Care):

Monitored intravenous (IV) infusion of certified, viable UC-MSCs in sterile saline suspension under continuous vital telemetry.
Nutritional counseling for hepatic metabolic support, gentle mobility coaching, and stress-reduction guidelines.

Days 4–5 (Post-Infusion Assessment & Rest):

Repeat clinical evaluation of vital stability and liver parameters, tolerance check, and issuance of post-discharge hepatology advice.

Day 6 (Discharge & Return Flight Clearance):

Final hepatology sign-off and issuance of fit-to-fly documentation.

Longitudinal Remote Follow-Up:

Scheduled telemedicine consultations at Months 1, 3, 6, and 12, coordinated directly with your home hepatologist.

Strategic Hospital Advantages

Why Receive Care at Our Specialized Center in India?

Super-specialist clinical oversight, cGMP cleanroom facilities, and high cell viability

Hepatology Oversight: Protocols supervised directly by post-doctoral DM/DNB Hepatologists and cellular biologists.

Cell Purity & Traceability:

Umbilical cord-derived MSCs sourced from screened full-term donors, processed in ISO Class 5 cleanrooms, and verified for high viability ($>85\%$), sterility, negative mycoplasma, endotoxin safety, and flow cytometry immunophenotyping (CD73+, CD90+, CD105+ / CD34-, CD45-, HLA-DR-).

Transparent Pricing Scope:

Standard comprehensive packages range from $5,200 to $7,800 USD (inclusive of cellular biologicals, hospital daycare fees, physician consultations, and baseline routine tests). Detailed written estimates are provided prior to travel.

Estimated Costs & Package Inclusions

Treatment Costs & Comparative Package Inclusions

Transparent international pricing with comprehensive hospital, cellular, and logistical inclusions

Package Range Transparent Pricing

$5,200 – $7,800 USD

(Comprehensive package covering targeted UC-MSCs, procedural suites, specialist fees, and 12-month monitoring).

Clinical Objective Investigational Care

Autoimmune Hepatitis (AIH) Care

(Administered under strict ISO Class 5 cleanroom standards and institutional ethics oversight).

Country / Region	Typical Package Range	Waiting Period	Clinical Accreditation
India (Our Specialized Centers)	$5,200 – $7,800 USD	1 – 2 Weeks	NABH / JCI Accredited
United States	$35,000 – $65,000 USD	3 – 6 Months	Clinical Trial Gated
Germany & Switzerland	$28,000 – $55,000 USD	2 – 4 Months	Private Specialty Only
Panama / Mexico	$18,000 – $32,000 USD	2 – 4 Weeks	Variable Regional

Package Inclusions:

Pre-procedure specialty diagnostics, baseline scans, and multidisciplinary doctor evaluations.

cGMP cleanroom certified cellular harvesting, flow-cytometry viability testing (>85%), and procedural suite fees.

Government Medical Visa (MED Visa) invitation assistance and complimentary chauffeured airport transfers.

Dedicated bilingual case coordinator and 12 months of structured remote post-procedure monitoring.

International Patient Services

Dedicated Support for International Patients & Families

Full medical concierge care, government visa assistance, and airport transit

Medical Visa (MED) Support:

Official hospital visa invitation letters issued within 24–48 hours for the patient and accompanying caregivers (with FRRO guidance).

Dedicated Case Coordinator:

A single English-speaking coordinator manages appointments, medical records, and hospital logistics.

Airport & Ground Transit:

Complimentary private airport pick-up/drop-off with dedicated wheelchair-accessible transport.

Language & Dietary Care:

Multi-language translators (Arabic, Russian, French) and access to customized hepatic-friendly meals (Low-sodium, Vegetarian, Halal, Continental).

Travel & Logistics

Logistics & Accessible Accommodation

Daycare outpatient protocol, nearby wheelchair-accessible partner lodging, and daily transfers

Daycare Model:

Treatments occur in morning sessions, allowing the patient to rest in private quarters each afternoon to avoid travel and physical exhaustion.

Nearby Lodging:

Partner 4-star hotels and serviced apartments located within 10–15 minutes of the hospital, featuring step-free access, elevators, roll-in showers, and kitchenettes.

Direct Daily Commute:

Arranged transfers between local lodging and the medical center to prevent transit fatigue.

Regulatory & Ethics

Regulatory Disclosures & Ethical Declarations

Statutory compliance under ICMR-DBT National Guidelines and vital medication advisories

Investigational Therapy Notice:

Cell-based therapies for Autoimmune Hepatitis are categorized as investigational cellular treatments under the National Guidelines for Stem Cell Research published by the Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organisation (CDSCO). They are not marketed as an approved routine standard of care or a definitive cure.

Severe Flare & Rebound Warning:

Patients must never discontinue, taper, or modify their standard immunosuppressive medications (e.g., Azathioprine, Prednisolone, Budesonide, Mycophenolate) without explicit instructions from their primary treating hepatologist. Abrupt cessation risks triggering life-threatening rebound autoimmune hepatitis.

Ethical Standards:

All biological procurement complies with informed maternal consent, donor screening, and statutory bioethics standards.

Scientific Citations

Peer-Reviewed Clinical Literature & Scientific Context

Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms

Scientific Notice on Study Types:

Scientific Notice on Study Types: Autoimmune Hepatitis is a complex immunopathologic condition. References 1 and 2 report on translational reviews and preclinical mechanisms describing how mesenchymal stem cells downregulate hepatic inflammation and modulate regulatory T-cells. References 3 and 4 discuss clinical trial applications and emerging cell-derived platforms in autoimmune liver disease indexed on PubMed.

Stem Cell Therapies for Autoimmune Hepatitis (Stem Cell Res Ther / PubMed)

PubMed: 33633826 ↗ PMC7887681 ↗

Mesenchymal stem cell-based treatment in autoimmune liver diseases: underlying roles, advantages and challenges. Ther Adv Chronic Dis / PMC, 2021; PMID: 33633826 | PMCID: PMC7887681.

Clinical Context: Evaluates the clinical and preclinical landscape of MSCs in autoimmune hepatitis and cholangiopathies, highlighting anti-fibrotic action, low immunogenicity, and the necessity of controlled clinical trials.

Mesenchymal Stem Cell-Derived Exosomes in Autoimmune Hepatitis (Biomolecules / PubMed)

PubMed: 39595530 ↗ PMC11592114 ↗

Mesenchymal Stem Cell-Derived Exosomes: Emerging as a Promising Cell-Free Therapeutic Strategy for Autoimmune Hepatitis. Biomolecules, 2024; 14(11): 1353. PMID: 39595530 | PMCID: PMC11592114.

Clinical Context: Explores cell-derived secretome and vesicular delivery systems, detailing significant regulatory effects on immune cell cascades and the modification of hepatic microenvironments.

Harnessing Mesenchymal Stromal Cells for Liver Disease Therapy (Frontiers in Medicine, 2026)

Harnessing mesenchymal stromal cells for liver disease therapy: from cellular mechanism to clinical application. Front Med, 2026; Frontiers in Medicine.

Clinical Context: Outlines the multi-dimensional therapeutic actions of MSCs—immunomodulation, direct anti-fibrotic intervention, and promotion of hepatic regeneration in immune-mediated and chronic liver injuries.

Frequently Asked Questions

Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Autoimmune Hepatitis (AIH)

No, stem cell therapy is not recognized as a definitive or permanent cure. Under Indian Council of Medical Research (ICMR) and CDSCO clinical guidelines, cellular therapy for Autoimmune Hepatitis (AIH) is an investigational and supportive treatment. Its objective is to modulate pathogenic immune activity, release neurotrophic and cytoprotective paracrine factors, and slow down progression to improve quality of life under strict institutional ethics oversight.

Umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) act primarily through paracrine immunomodulation and secretome release. They downregulate pro-inflammatory cytokines, modulate hyperactive cytotoxic T-cells, inhibit excessive fibrotic scarring, and secrete restorative growth factors (such as HGF, VEGF, BDNF, and IL-10) that support microvascular circulation and cellular tissue survival.

The comprehensive outpatient daycare protocol requires approximately 4 to 6 Days in India. Day 1 involves baseline diagnostic blood panels, imaging, and specialty evaluation by a Gastroenterology & Hepatology board. Days 2 and 3 include monitored cellular infusion (Targeted Intravenous (IV) Infusion with Vital Monitoring) under vital telemetry, followed by post-procedure observation, mobility guidance, and fit-to-fly clearance on Day 6.

Certified cGMP-processed allogeneic UC-MSCs possess an established safety profile with zero risk of donor graft-versus-host disease (GvHD). Common transient reactions include self-limiting low-grade fever (< 38°C / 100.4°F), temporary fatigue, or mild injection-site soreness resolving within 24–48 hours. Patients undergo pre-infusion safety checks and continuous bedside monitoring.

Comprehensive international treatment packages range from $5,200 – $7,800 USD. This transparent pricing includes clinical-grade certified UC-MSC biologicals (flow-cytometry verified >85% viability), specialized hospital procedural suites, doctor consultations, routine baseline safety labs, medical visa (MED) invitation support, and 12 months of structured remote follow-up.

Before confirming medical travel, international patients must submit recent clinical diagnostic reports (specialty scans, blood chemistry, disease-specific antibody panels, or biopsy records) for preliminary evaluation by our medical board. Our clinical team reviews the records within 24 to 48 hours to confirm candidacy before issuing official visa invitation letters.

✓
Accreditations: NABH-Accredited Inpatient Tertiary Hospital | ISO Class 5 Cleanroom Processing
✓
Statutory Oversight: Institutional Committee for Stem Cell Research (IC-SCR) & Registered Institutional Ethics Committee (IEC)
✓
Regulatory Alignment: Conducted under the ICMR-DBT National Guidelines for Stem Cell Research (India)
✓
Direct International Triage:
WhatsApp / Phone: +91-7744005984

Email: contact@stemcelltherapyinindia.com

PARTNER HOSPITALS TREATING AUTOIMMUNE HEPATITIS (AIH):

RELATED PROTOCOLS:

Category	Details	Cost
🏥 Medical Procedure Cellular processing & specialist fees	Standard Protocol	$4,200
🏨 Accommodation Private room near hospital	7 nights @ $35/night	$245
🍽 Meals & Nutrition Dietary plan for patient & companions	7 days × 2 person(s) @ $25/day	$350
🚗 Local Transfers & Visa	Ground handling & priority transit	$200
💎 Total Estimated Budget All-inclusive medical + logistics	Combined estimate for 7 days (2 travelers)	$4,995